Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

LIPI- PROTECT-2 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP2) (LPP2)

13. november 2026 opdateret af: Institut Pasteur de Lille

Effect of the Dietary Supplement LIPI-PROTECT-2 on Plasma LDL Cholesterol Concentration in Subjects With Moderate Hypercholesterolemia: A Pilot Study.

This is a multicenter, uncontrolled pilot study evaluating changes in plasma LDL-cholesterol (LDL-C) concentrations before and after 3 months of intake of the dietary supplement LIPI-PROTECT-2.The main objective of this clinical trial is to evaluate the effect of LIPI-PROTECT-2 on plasma LDL-C concentration after 3 months of supplementation in participants with untreated moderate hypercholesterolemia.A mean reduction in plasma LDL-C levels of approximately 14% (0.20 g/L) is expected after 3 months of supplementation.The primary endpoint is the absolute (g/L) and relative (%) change in plasma LDL-C concentration between baseline and Month 3.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for coronary cardiovascular disease. In individuals at low cardiovascular risk, lifestyle and dietary measures are recommended to reduce LDL-C levels and/or overall cardiovascular risk. Dietary supplements may be considered as part of these measures when their efficacy has been demonstrated.LIPI-PROTECT-2 is a dietary supplement containing plant extracts and vitamins that may contribute to reducing plasma LDL-C levels. Some of its individual active ingredients have previously been investigated in clinical studies and have shown an LDL-C-lowering effect. However, the combination of these active ingredients has not previously been evaluated in a clinical study.This pilot, multicenter, uncontrolled study is designed to provide preliminary estimates of the effect of LIPI-PROTECT-2 in adults with untreated moderate hypercholesterolemia.A total of 20 men and women aged 18 to 65 years with untreated moderate hypercholesterolemia will be included. Participants will have an LDL-C level ≥1.5 g/L and a low cardiovascular risk. They will consume LIPI-PROTECT-2 for 3 months and will be required to maintain stable body weight, dietary habits, and physical activity throughout the study.The primary objective is to assess the effect of LIPI-PROTECT-2 on plasma LDL-C concentration after 3 months of supplementation. The primary outcome will be the absolute and relative change in LDL-C concentration between baseline and Month 3. A mean reduction of approximately 14% (0.20 g/L) in LDL-C is expected after 3 months of supplementation.Secondary objectives are to evaluate the effect of LIPI-PROTECT-2 after 1 and 3 months compared with baseline on body weight, body mass index, waist circumference, systolic and diastolic blood pressure, resting heart rate, fasting glucose, LDL-C, non-HDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, LDL-C/HDL-C and total cholesterol/HDL-C ratios, and the atherogenic index (non-HDL-C/HDL-C).Safety will also be assessed by comparing selected laboratory parameters between baseline and Month 3, including AST, ALT, gamma-glutamyl transferase, creatine kinase, lactate dehydrogenase, bilirubin, creatinine, and urea. Adherence to the dietary supplement will be assessed throughout the study.Participants with high or very high cardiovascular risk, lipid-lowering treatment, diabetes, severe chronic diseases, or concomitant treatments likely to interfere with the assessment of efficacy or safety will be excluded.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

20

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Nord
      • Lille, Nord, Frankrig, 59019
    • Vaucluse
      • Avignon, Vaucluse, Frankrig, 84140

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Men and women aged 18-65 years For women :If pre-menopausal: effective non-estrogenic* contraception initiated at least 2 cycles prior and maintained throughout the studyIf post-menopausal: not receiving estrogenic* Hormone Replacement Therapy (HRT)
  • LDL-cholesterol ≥ 1.5 g/L (calculated using the Friedewald formula)
  • Aware of their hypercholesterolemia and previously informed about the associated lifestyle and dietary measures
  • BMI between 20 and 35 kg/m² (inclusive)
  • Stable weight, dietary habits, and physical activity level for at least 3 months prior to the start of the study, with agreement to maintain them throughout the study
  • Willing to comply with study requirements
  • Signed informed consent

Exclusion Criteria:

  • Subjects receiving lipid-lowering or anti-dyslipidemic therapy (statins, ezetimibe, cholestyramine, fibrates, etc.)
  • Subjects with triglyceride levels > 4 g/L
  • Subjects requiring immediate lipid-lowering therapy
  • Subjects with diabetes (whether treated with medication or not, or diagnosed during the initial visit based on fasting blood glucose > 1.26 g/L)
  • Subjects receiving beta-blockers and/or diuretics
  • Subjects at high or very high cardiovascular risk according to ESC/EAS 2025 guidelines (assessed using the SCORE2 score, Appendix 2)
  • Subjects receiving anticoagulant therapy
  • Subjects receiving antiretroviral therapy
  • Subjects requiring immediate dietary intervention, or exhibiting fluctuating eating habits or an eating disorder (anorexia, bulimia, binge eating disorder)
  • Subjects on unstable treatment (initiated less than three months prior) or requiring the initiation of treatment during the study that, in the investigator's opinion, could interfere with the assessment of study endpoints (efficacy parameters: LDL, TG, HDL, blood glucose, blood pressure, weight; safety parameters: markers of hepatic, muscular, or renal function)
  • Subjects who have consumed dietary supplements or functional foods capable of affecting cholesterol or triglyceride levels (phytosterols, phytostanols, red yeast rice, policosanols, beta-glucans at doses exceeding 3 g/day, artichoke or garlic extracts, probiotics, etc.) within the last 6 weeks
  • Subjects suffering from a severe chronic condition deemed incompatible with participation in the study by the investigator (serious digestive disorders, renal insufficiency, coronary artery disease, immunodeficiency, heart failure, rhythm disorders, active malignancy, hematological disease)
  • Subjects with an allergy to any of the components of LIPI-PROTECT-2 Pregnant or breastfeeding women, or women intending to become pregnant within the next 4 months Subjects under legal protection (guardianship/curatorship, deprivation of liberty) or not covered by a social security scheme
  • Subjects participating in another clinical study or currently within the exclusion period of another study
  • Subjects whose condition is judged by the principal investigator or a qualified co-investigator deems that their health status or concomitant treatments are incompatible with the proper conduct of the clinical study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Food supplement group

Three tablets of LIPI-PROTECT-2 per day (1 at the end or after breakfast and 2 during dinner). Food supplements are consumed during 3 months by healthy volunteers

All subjects will consume 4 capsules per day during the entire intervention period, i.e. 12 weeks between V0 and V3, distributed as follows: 2 capsules in the morning at the end of or after breakfast (no taking on an empty stomach) and 2 capsules in the evening during dinner. If a dose is missed, 1 capsule can be taken at the next dose

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To evaluate the effect of LIPI-PROTECT-2 on plasma LDL-cholesterol concentration (absolute value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia
Tidsramme: To baseline at 3 months

To evaluate the absolute (g/L) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3).

To baseline at 3 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To evaluate the effect of LIPI-PROTECT-2 on plasma LDL-cholesterol concentration (relative value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia.
Tidsramme: To baseline at 3 months

To evaluate the relative (%) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3).

To baseline at 3 months
To evaluate the effect of LIPI-PROTECT-2 on LDL cholesterol.
Tidsramme: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in LDL cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on Non HDL cholesterol.
Tidsramme: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in Non HDL cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on total cholesterol.
Tidsramme: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in total cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on HDL cholesterol.
Tidsramme: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in HDL cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on triglycerides.
Tidsramme: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on triglycerides in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on non HDL cholesterol/LDL (atherogenic index).
Tidsramme: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non HDL cholesterol/LDL (atherogenic index) (ratio).

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on ratio LDL/HDL.
Tidsramme: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non ratio LDL/HDL (ratio).

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on ratio total cholesterol/HDL.
Tidsramme: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on ratio total cholesterol/HDL (ratio).

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on fasting blood glucose levels.
Tidsramme: At baseline, 1 month and 3 months

Variation in fasting blood glucose (unit: g/l) between VS, V1, and V3

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on weight.
Tidsramme: At baseline, 1 month and 3 months

Changes in weight (unit : kilograms) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on Body Mass Index (BMI).
Tidsramme: At baseline, 1 month and 3 months

Changes in BMI (weight and height will be combined to report BMI) in kg/m^2between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on waist circumference.
Tidsramme: At baseline, 1 month and 3 months

Changes in waist circumference (unit: cm) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on arterial blood pressure
Tidsramme: At baseline, 1 month and 3 months

Variation in systolic blood pressure and diastolic blood pressure (unit: mm Hg) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on heart rate
Tidsramme: At baseline, 1 month and 3 months

Variation in Heart rate (unit: Pul/min) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the safety of LIPI-PROTECT-2 on hepatic metabolism: ASAT/ALAT, GGT
Tidsramme: At baseline and 3 months

Changes in safety biomarkers : ASAT/ALAT and GGT(unit: UI/l) between baseline and V3 .

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-2 on hepatic metabolism : Creatinine, bilirubin
Tidsramme: At baseline and 3 months

Changes in safety biomarkers : Creatinine, bilirubin (unit: mg/dl) between baseline and V3.

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-2 on renal metabolism : Urea
Tidsramme: At baseline and 3 months

Changes in safety biomarkers : Urea (unit: mg/dl) between baseline and V3.

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-2 on renal metabolism : Creatinine Phophoskinase (CPK)
Tidsramme: At baseline and 3 months

Changes in safety biomarkers : CPK (unit : UI/l) between baseline and V3.

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-2 on Renal metabolism : Lactate Deshydrogenase (LDH)
Tidsramme: At baseline and 3 months

Changes in safety biomarkers : LDH (unit : UI/l) between baseline and V3.

At baseline and 3 months
To assess adherence to LIPI-PROTECT-2 consumption by pillbox weighing
Tidsramme: At baseline, 1 month and 3 months

Adherence assessed by weighing the pillbox at each visit and comparing the weight with the initial weight recorded at baseline (V0).

At baseline, 1 month and 3 months
To assess self-reported adherence to LIPI-PROTECT-2 consumption
Tidsramme: At baseline, 1 month, 2 months and 3 months

Adherence assessed through participant self-reporting of supplement consumption and missed doses.

At baseline, 1 month, 2 months and 3 months
To assess adherence to LIPI-PROTECT-2 consumption by counting returned tablets
Tidsramme: At 3 months

Adherence assessed by counting the remaining tablets returned by participants at the end of the study.

At 3 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studiestol: Coralie BERTHIER, PhD, Institut Pasteur of Lille

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

4. november 2026

Primær færdiggørelse (Anslået)

30. marts 2027

Studieafslutning (Anslået)

30. marts 2027

Datoer for studieregistrering

Først indsendt

13. november 2026

Først indsendt, der opfyldte QC-kriterier

13. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2026-A00950-51

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .